AI, Biotech, and Longevity
AI is accelerating biological research at every level — from molecular design to whole-organism aging — making longer healthy lifespans more plausible than they have ever been, while keeping radical extension speculative.
Key facts
- Hallmarks of aging framework first published 2013, updated 2023 (López-Otín et al.).
- Partial reprogramming reverses age markers in mice without inducing tumors (Ocampo et al. 2016; subsequent work).
- AI-designed therapeutics have entered Phase 1 and 2 human trials.
- Altos Labs has raised >$3B for cellular reprogramming research.
- AlphaFold 3 (2024) extended structure prediction to ligands and nucleic acids.
Designing Biology
Generative protein design (RFdiffusion, Chroma, ESM3), CRISPR base and prime editing, AI-guided cellular engineering (Mammoth, Beam, Verve), and machine-learning-assisted directed evolution are transforming what biology can engineer.
Isomorphic Labs (Alphabet), Insilico Medicine, Recursion, Exscientia, and Genesis Therapeutics have moved AI-designed therapeutics into the clinic.
The Biology of Aging
Hallmarks-of-aging frameworks (López-Otín et al. 2013, updated 2023), partial reprogramming (Ocampo, Belmonte, Altos Labs), senolytics, metformin (TAME trial), and rapamycin-class molecules are subjects of active human trials.
None yet extend healthspan in healthy humans, though biomarker improvements are routinely reported.
Platforms and Companies
Altos Labs (>$3B funded), Calico (Alphabet), Retro Biosciences (OpenAI-backed), Loyal (dogs), Genentech, and dozens of biotech startups are pursuing aging biology with AI-heavy methods.
Reprogramming, parabiosis-inspired plasma therapy, and senolytic strategies compete for primacy.
Realistic Outlook
Expect meaningful but incremental healthspan gains over 10–20 years. Radical life extension remains speculative; healthy longevity is plausible and increasingly well-funded.
Public health, vaccination, and chronic-disease management likely add more decades of healthy life in the near term than any single anti-aging molecule.
Ethics and Distribution
If healthspan-extending therapies become expensive, they will widen lifespan inequality before they narrow it. The pricing and access debate echoes early HIV antiretrovirals.
Gene-editing of embryos (He Jiankui case, 2018) remains globally condemned; somatic editing in adults is the live ethical frontier.
Frequently asked
Will we live to 200?
+
No credible near-term path. Adding healthy decades to current lifespans is plausible over the coming generation; doubling lifespan remains speculative.
Does any drug extend lifespan in humans?
+
Not proven. Metformin (TAME), rapamycin analogs, and senolytics are in trials but none has demonstrated lifespan extension in healthy humans.
Is gene editing safe?
+
Somatic editing (e.g., Casgevy for sickle-cell, approved 2023) is increasingly clinical reality. Germline editing remains globally restricted.
Sources & further reading
Continue in this series
Macroeconomics
The Post-AGI Economy
Philosophy
Transhumanism and Human Enhancement
Long-termism
AI, Space, and the Long-Term Future
Human Condition
Meaning, Purpose, and Identity in an AI Era
Scenarios
Scenarios for the Next Century